Therapeutic bacteriophage compositions
Inventors
Shaw, Karen Joy • MORALES, Sandra P. • MEARNS, Gillian • RANKIN, Deborah A. • SMREKAR, Frenk
Assignees
Publication Number
US-10517908-B2
Publication Date
2019-12-31
Expiration Date
2036-08-15
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages selected from Sa87, J-Sa36, Sa83, J-Sa37, or mutants thereof, use of the same for medical or non-medical applications, kits, bandage, and wound dressing comprising the same.
Core Innovation
The invention is a bacteriophage composition comprising one or more bacteriophages selected from Sa87, J-Sa36, Sa83, J-Sa37, or mutants thereof. This composition is designed for both medical and non-medical applications, with particular utility in treating pulmonary bacterial infections caused by Staphylococcus aureus. The composition can be used as a medicament for treating such infections, administered to a subject by suitable routes, and is also provided as part of kits, bandages, or wound dressings.
The problem addressed is the increasing resistance of human pathogens, specifically Staphylococcus aureus, to antibiotics. There is a significant need for new treatment options that circumvent antibiotic resistance mechanisms, are effective against biofilms, and do not disrupt the native gut flora. Conventional approaches and existing bacteriophage combinations may be subject to rapid development of bacterial resistance or antagonistic effects among phage components.
The core of the invention is the discovery that specific combinations of bacteriophages, particularly Sa87, J-Sa36, and Sa83, exhibit improved therapeutic efficacy and reduce the development of resistance in S. aureus compared to conventional compositions, including combinations with J-Sa37. The invention also encompasses compositions with mutants of these phages, which retain the ability to lyse S. aureus. The bacteriophage composition can be used directly to treat infections, kill S. aureus on surfaces, and be included in medical devices and formulations.
Claims Coverage
There are four independent inventive features identified in the patent claims.
Treating a Staphylococcus aureus bacterial infection using a specific bacteriophage composition
A method comprises administering a bacteriophage composition that includes one or more bacteriophages capable of infecting and lysing Staphylococcus aureus. The bacteriophages are selected from Sa87, J-Sa36, and Sa83. The core inventive feature is the use of these defined phages for the treatment, targeting the infection with specified phage types.
Treating pulmonary bacterial infection with specified bacteriophage composition
A method involves treating a pulmonary bacterial infection in a subject by administering a bacteriophage composition consisting of one or more bacteriophages capable of infecting and lysing Staphylococcus aureus, selected from Sa87, J-Sa36, and Sa83. The inventive feature is the application of this composition specifically for pulmonary S. aureus infections.
Killing Staphylococcus aureus bacteria on a surface using the bacteriophage composition
This method applies a bacteriophage composition comprising one or more of Sa87, J-Sa36, and Sa83 to a surface to kill Staphylococcus aureus bacteria present. The inventive feature focuses on non-systemic, external application for decontamination purposes.
Non-medical method of killing Staphylococcus aureus on food or crops
A method for non-medical killing of Staphylococcus aureus bacteria on a food product or a crop involves applying a bacteriophage composition comprising one or more bacteriophages from Sa87, J-Sa36, and Sa83. The inventive feature is the application of these specific phages in agricultural or food hygiene settings for bacterial decontamination.
The inventive features define methods using a bacteriophage composition comprising one or more of Sa87, J-Sa36, and Sa83 for medical treatment, pulmonary infection therapy, decontamination of surfaces, and non-medical agricultural or food applications.
Stated Advantages
The bacteriophage composition shows improved therapeutic efficacy against Staphylococcus aureus compared to conventional compositions.
Compositions comprising Sa87, J-Sa36, and Sa83 reduce bacteriophage antagonism and the development of resistance in Staphylococcus aureus target bacteria.
The composition is efficacious against a broad spectrum of Staphylococcus aureus strains.
Combination with an antibiotic can provide enhanced therapeutic efficacy, particularly for pulmonary infections.
Topical and surface-directed formulations enable targeted, high-concentration application for effective decontamination or localized treatment.
Documented Applications
Treatment of Staphylococcus aureus infections, including pulmonary bacterial infections, in human and animal subjects.
Killing Staphylococcus aureus bacteria on surfaces such as skin, equipment, bedding, furniture, walls, and floors, including clinical environments.
Use in non-medical applications such as disinfecting food products and crops for food hygiene and agriculture.
Inclusion in kits with dosing instructions for medical or non-medical applications.
Incorporation into bandages or wound dressings for direct application to wounds that may contain Staphylococcus aureus.
Interested in licensing this patent?